Cambridge Healthtech Institute’s Second Annual
PK/PD of Multi-Domain Proteins
Bench to Bedside Translation of Bispecifics, ADCs, and Antibody Fragments
Part of the Tenth Annual PEGS: the essential protein engineering summit
May 5-6 2014 | Seaport World Trade Center | Boston, MA
Cambridge Healthtech Institute’s Second Annual PK/PD of Multi-Domain Proteins will address how PK/PD and ADME are driving molecular construct design, modeling for multiple targets, and unique characteristics of ADCs, bispecifics, and fragments. Risk management plans will be reviewed from study design to an impact assessment plan and experts will present integrated bioanalytical strategies for attendees to take back to their labs. Optimizing PK/PD is crucial to the clinical success of novel drug candidates; this event will help to ensure attendees move forward with the best analytical strategy for bench to bedside translation.
Harnessing the Patient’s Immune System to Combat Cancer
Bahija Jallal, Ph.D., Executive Vice President, MedImmune
Building One of the World’s Top Biotechnology Companies from the Ground Up: The Story of Regeneron
George D. Yancopoulos, M.D., Ph.D., President, Regeneron Laboratories; CSO, Regeneron Pharmaceuticals, Inc.
OPENING KEYNOTE PRESENTATION
Application of PK/PD in Modality Design
Mohammad Tabrizi, Ph.D., Head & Senior Fellow, PK/PD, Merck
Which Parameters Do I Need to Optimize Design of a Successful Antibody-Drug Conjugate?
Alison Betts, Modeling and Simulation Leader, Associate Research Fellow, Translational Research Group, Pharmacokinetics, Dynamics & Metabolism, Pfizer Global R&D
PK Optimization and Preclinical PK of Novel Bispecific Antibody against FIXa and X for the Treatment of Hemophilia A
Kenta Haraya, Researcher, Chugai Pharmaceutical Co., Ltd.
Bispecific Antibody Formats Evaluated for Pre-Targeting
K. Dane Wittrup, Ph.D., J.R. Mares Professor, Chemical Engineering & Bioengineering, Massachusetts Institute of Technology
Considerations for Design of Bispecific Modalities
Isabel Figueroa, Principal Scientist, PK/PD, Merck
PK/PD Modeling and Simulation Supporting Preclinical and Clinical Development of ADC
Xiang-Qing Yu, Ph.D., Principal Clinical Pharmacokineticist, MedImmune
Understanding the Insights into the ADME of Antibody-Drug Conjugates (ADC) Impacts ADC Development
Ben-Quan Shen, M.D., Senior Scientist, PKPD, Genentech, Inc.
Employing PK/PD Modeling and Simulation to Guide ADC Development
Dhaval K. Shah, Ph.D., Assistant Professor, Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo
Mechanism-Based PK/PD Modeling of Antibody-Drug Conjugate Disposition and Action
Siddharth Sukumaran, Ph.D., Associate Scientist, Pharmacokinetics and Pharmacodynamics, Genentech, Inc.
PK/PD Considerations for Design of Combination Therapies
Meric Ovacik, Senior Scientist, PK/PD, Merck
An Integrated Analytical Strategy for Biologics
Peter Lloyd, Head, PK/PD, Biologics, Novartis
CLOSING KEYNOTE presentation
Impact of Immunogenicity on PK Profiles of Novel Large Molecule Constructs
Vibha Jawa, Ph.D., Principal Scientist, Clinical Immunology, Amgen (Tentative)